Hepatitis

Show Only Open Trials
1.

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

  • Study Status: Open to Enrollment
  • Sponsor: Bristol-Myers Squibb
  • Disease Status and/or Stage: Chronic Hepatitis C, Untreated or Previously Treated
  • Protocol ID: BMS AI452021
2.

GS-US-321-0105: GS-6624 in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Advanced Liver Fibrosis as a Result of NASH (non-lcoholic steatohepatitis)
3.

GS-US-321-0102: GS-6624 in the Prevention of Progression of Liver Fibrosis in Subjects With With Primary Sclerosing Cholangitis (PSC)

  • Study Status: Open to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Primary Sclerosing Cholangtis (PSC)
  • Protocol ID: GS-US-321-0102
4.

A Study Evaluating GS-9620 in Virologically Suppressed Subjects With Chronic Hepatitis B Virus Infection (GS-US-283-0102)

  • Study Status: Closed to Enrollment
  • Sponsor: Gilead
  • Disease Status and/or Stage: Chronic Hepatitis B
  • Protocol ID: GS-US-283-0102
6.

A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects

  • Study Status: Open to Enrollment
  • Sponsor: NIAID
  • Disease Status and/or Stage: HIV/Hepatitis C Co-Infection

Top of page